Program Overview
This CME/CE webcast, chaired by Fred D. Lublin, MD, will analyze current best practices for utilizing fumarate-based therapeutics to improve outcomes in patients with multiple sclerosis (MS). The expert faculty will first review the mechanism of action and targets of fumarates in the MS treatment landscape. Following, current trial data of fumarate-based therapeutics in MS will be reviewed and clinical implications debated in an interactive panel format. The faculty will conclude with a discussion of clinical strategies for fumarate-based therapeutics, analyzing pros and cons of therapy while considering hot topics such as vaccination status and future considerations.
Target Audience
Healthcare professionals who care for patients with multiple sclerosis, including neurologists, primary care physicians, physician’s assistants, nurse practitioners and other supporting clinicians
Learning Objectives
- Understand the pharmacology science of fumarate-based therapeutics and the importance of drugs vs. pro-drugs bioavailability
- Review the safety and efficacy data for novel oral fumarate-based therapeutics
- Discuss strategies to increase patient adherence to treatment, including adverse events, route of administration, and financial impact
- Review clinical applications of novel oral fumarate-based therapeutics for the treatment of Relapsing MS, CIS, and Active Secondary MS, including switching therapies
Agenda
I. The Pharmacology Science Review of Fumarate-based Therapeutics and the Importance of Bioavailability: Drugs vs. Pro-drugs
II. Clinical Trial Review for Novel Oral Fumarate-based Therapeutics to Treat Patients with MS
III. Increasing Patient Adherence to Treatment by Mitigating Adverse Events and Patient Education
IV. Developing Clinical Treatment Plans for Novel Oral Fumarate-based Therapeutics to Improve Outcomes in Patients with Relapsing MS, CIS, and Active Secondary MS, Including Switching Therapies
I.V Faculty Panel Discussion
Faculty
Fred D. Lublin, MD (Course Chair)
Saunders Family Professor of Neurology Director
The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Icahn School of Medicine at Mount Sinai
New York, New York
Patricia Coyle, MD
Professor and Vice Chair (Clinical Affairs)
Director, MS Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, New York
Stephen Krieger, MD
Professor of Neurology
Corinne Goldsmith Dickinson Center for MS
Department of Neurology
Icahn School of Medicine at Mount Sinai
New York, New York
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
| Faculty | Relationship Identified With: |
| Fred D. Lublin, MD | Consultant/Advisor: Acorda Therapeutics; Actelion Pharmaceuticals US, Inc.; Apitope; Atara Biotherapeutics; Avotres Inc.; Banner Life Sciences; Biogen; Brainstorm Cell Therapeutics; Bristol-Myers Squibb; Celgene Corporation; EMD Serono, Inc.; Entelexo Biotherapeutics; Genentech, Inc.; GW Pharmaceuticals; Horizon Therapeutics; Immunic Therapeutics; Janssen Global Services, LLC; Jazz Pharmaceuticals; Labcorp; Mapi-Pharma Ltd.; MedDay Pharmaceuticals; Medimmune, LLC; Mylan; Neurogene; Novartis AG; Orion Biotechnology; Receptos; Roche; Sanofi Genzyme; Teva Pharmaceuticals; TG Therapeutics; Viela Bio, Inc.
Grant/Research Support: Actelion Pharmaceuticals US, Inc.; Biogen; Brainstorm Cell Therapeutics; Novartis AG; Sanofi Genzyme Speaker’s Bureau: Sanofi Genzyme Stock Options: Avotres Inc. |
| Patricia Coyle, MD | Consultant/Advisor: Accordant, A CVS Caremark Company; Alexion Pharmaceuticals, Inc.; Bayer AG; Biogen; Bristol-Myers Squibb; Celgene Corporation; EMD Serono, Inc.; Genentech, Inc.; GlaxoSmithKline; Horizon Therapeutics; Janssen Global Services, LLC; Novartis AG; Roche; Sanofi Genzyme; TG Therapeutics; Viela Bio, Inc.
Grant/Research Support: Actelion Pharmaceuticals US, Inc.; Alkermes; Corrona LLC; Genentech, Inc.; MedDay Pharmaceuticals; Novartis AG; Roche; Sanofi Genzyme Speaker’s Bureau: Biogen; Janssen Global Services, LLC |
| Stephen Krieger, MD | Consultant/Advisor: Biogen; EMD Serono, Inc.; Genentech, Inc.; Mallinckrodt Pharmaceuticals; MedDay Pharmaceuticals; Novartis AG; Sanofi Genzyme; Teva Pharmaceuticals; TG Therapeutics
Grant/Research Support: Biogen; Novartis AG Speaker’s Bureau: Biogen; EMD Serono, Inc.; Genentech, Inc.; Novartis AG |
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Gabrielle Fiorelli, CRNP; Nicole McMenamin and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour, including 1.0 Pharmacotherapeutic Contact Hour (Provider # P0491).
Clinicians should claim only the credit commensurate with the extent of their participation in the activity.
Financial Support
This activity has been supported by an independent educational grant from Banner Life Sciences.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Banner Life Sciences do not recommend the use of any agent outside of the labeled indications.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 66% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].
